Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy

Katrin Pfütze; Axel Benner; Michael Hoffmeister; Lina Jansen; Rongxi Yang; Hendrik Bläker; Esther Herpel; Alexis Ulrich; Cornelia M Ulrich; Jenny Chang-Claude; Hermann Brenner; Barbara Burwinkel

doi:10.1016/j.ygeno.2015.10.002

Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy

Genomics. 2015 Dec;106(6):348-54. doi: 10.1016/j.ygeno.2015.10.002. Epub 2015 Oct 21.

Authors

Affiliations

¹ Helmholtz-University Group Molecular Epidemiology, German Cancer Research Center (DKFZ), Germany; Molecular Biology of Breast Cancer, Department of Obstetrics and Gynecology, University of Heidelberg, Germany. Electronic address: [email protected].
² Division of Biostatistics, German Cancer Research Center (DKFZ), Germany.
³ Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Germany.
⁴ Helmholtz-University Group Molecular Epidemiology, German Cancer Research Center (DKFZ), Germany; Molecular Biology of Breast Cancer, Department of Obstetrics and Gynecology, University of Heidelberg, Germany.
⁵ Department of General Pathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
⁶ Department of General Pathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany; NCT Tissue Bank, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
⁷ Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany; Division of Molecular oncology, National Center for Tumor Diseases (NCT), Germany.
⁸ Division of Preventive Oncology, National Center for Tumor Diseases (NCT)/German Cancer Research Center (DKFZ), Germany.
⁹ Division of Cancer Epidemiology, Unit of Genetic Epidemiology, German Cancer Research Center (DKFZ), Germany.
¹⁰ Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Germany; German Cancer Research Center (DKTk)Germany.

PMID: 26453961
DOI: 10.1016/j.ygeno.2015.10.002

Abstract

DNA methylation variations in gene promoter regions are well documented tumor-specific alterations in human malignancies including colon cancer, which may influence tumor behavior and clinical outcome. As a subset of colon cancer patients does not benefit from adjuvant chemotherapy, predictive biomarkers are desirable. Here, we describe that DNA methylation levels at CpG loci of hyaluronoglucosaminidase 2 (HYLA2) could be used to identify stage II and III colon cancer patients who are most likely to benefit from 5-flourouracil (5-FU) chemotherapy with respect to overall survival and progression-free survival.

Keywords: 5-FU; Chemotherapy; Colorectal cancer; DNA methylation; HYAL2; Predictive marker; Prognostic marker.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic / therapeutic use
Cell Adhesion Molecules / genetics*
Colonic Neoplasms / drug therapy*
Colonic Neoplasms / genetics*
Colonic Neoplasms / pathology
CpG Islands / genetics
DNA Methylation*
Disease-Free Survival
Female
Fluorouracil / therapeutic use*
Follow-Up Studies
GPI-Linked Proteins / genetics
Humans
Hyaluronoglucosaminidase / genetics*
Kaplan-Meier Estimate
Male
Middle Aged
Multivariate Analysis
Neoplasm Staging
Prognosis
Regression Analysis
Treatment Outcome

Substances

Antimetabolites, Antineoplastic
Cell Adhesion Molecules
GPI-Linked Proteins
Hyal2 protein, human
Hyaluronoglucosaminidase
Fluorouracil